NCT06682806View on ClinicalTrials.gov

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 3, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

December 31, 2027

Conditions
Advanced Solid TumorEsophageal CancerMetastatic Solid TumorNon-small Cell Lung CancersSMARCA4 Gene Mutation
Interventions
DRUG

PRT3789

PRT3789 is administered as an intravenous infusion once weekly for 3 weeks

DRUG

pembrolizumab

Pembrolizumab is administered at 200 mg as an intravenous infusion over 30 min every 3 weeks

Trial Locations (9)

28040

Hospital Universitario Fundacion Jimenez Diaz - Servicio de Oncologia, Madrid

33401

Florida Cancer Specialists, West Palm Beach

37203

SCRI Oncology Partners, Nashville

Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research, Nashville

48201

Karmanos Cancer Institute, Detroit

77030

The University of Texas MD Anderson Cancer Center, Houston

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

08023

IOB - Next Oncology - Hospital Quironsalud Barcelona, Barcelona

START Barcelona - HM Nou Delfos, Barcelona

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Prelude Therapeutics

INDUSTRY

NCT06682806 - A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | Biotech Hunter | Biotech Hunter